Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

494

HTML

5259

Figures (1-1)

216

Tables (1-6)

205

Sum=6174

Publishing Process of This Article

Item

Count

Browse

1286

Download

1181

Sum=2467

Jun 7, 2013 (publication date) through Nov 3, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 7, 2013; 19(21): 3199-3206
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3199

Table 5 Interleukin-28B polymorphism in sofosbuvir and ABT-450 era

Group	Status before treatment	IL-28B CC (n)	IL-28B CT (n)	IL-28B TT (n)	SVR rate
Sofosbuvir
1	Untreated	5	4	1	100%
2	Untreated	4	4	1	100%
3	Untreated	4	4	2	100%
4	Untreated	4	5	2	100%
5	Untreated	2	6	2	60%
6	Untreated	3	6	1	100%
7	No response to prior therapy	2	5	3	10%
8	Untreated	11	12	2	84%
ABT-450
1	Untreated	10/9	7/7	2/2	95%
2	Untreated	5/4	7/7	2/2	93%
3	No or partial response to prior therapy	0/0	12/6	5/2	47%

IL-28B: Interleukin-28B; SVR: Sustained virologic response.

Citation: Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206
URL: https://www.wjgnet.com/1007-9327/full/v19/i21/3199.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i21.3199